Literature DB >> 7118065

Comparison of the effects of a cardioselective and a nonselective beta-blocker on portal hypertension in patients with cirrhosis.

P Hillon, D Lebrec, C Muńoz, M Jungers, G Goldfarb, J P Benhamou.   

Abstract

The effects on cardiac output and portal venous pressure of atenolol, a cardioselective beta-blocker, and propranolol, a nonselective beta-blocker, were compared in patients with portal hypertension due to cirrhosis. One hour after p.o. administration of 100 mg of atenolol, cardiac output decreased by 32%, and portal venous pressure by 16%; the decrease in cardiac output and the decrease in portal venous pressure were significantly correlated. One hour after p.o. administration of 40 mg of cardiac output and the decrease in portal venous pressure were not correlated. Whereas the decrease in cardiac output was similar after atenolol or propranolol, the decrease in portal venous pressure was significantly less marked after the former than after the latter beta-blocker. It is concluded that: (a) the decrease in portal venous pressure determined by atenolol results mainly from reduction in cardiac output; (b) the decrease in portal venous pressure determined by propranolol results not only from reduction in cardiac output, but also from extracardiac effects of this beta-blocker, and (c) atenolol might be less efficient in the prevention of recurrent gastrointestinal bleeding in cirrhosis, since the decrease in portal venous pressure is less marked than that which occurs with propranolol.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7118065     DOI: 10.1002/hep.1840020503

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  20 in total

Review 1.  Long term management of oesophageal varices.

Authors:  S K Sarin
Journal:  Drugs       Date:  1992       Impact factor: 9.546

Review 2.  Current management of the complications of portal hypertension: variceal bleeding and ascites.

Authors:  Nina Dib; Frédéric Oberti; Paul Calès
Journal:  CMAJ       Date:  2006-05-09       Impact factor: 8.262

3.  β-Blocker therapy ameliorates hypersplenism due to portal hypertension in children.

Authors:  Ujjal Poddar; Upender Shava; Surender Kumar Yachha; Jaya Agarwal; Sheo Kumar; Sanjay S Baijal; Anshu Srivastava
Journal:  Hepatol Int       Date:  2014-09-23       Impact factor: 6.047

4.  A study of the antiulcer mechanisms of propranolol in rats.

Authors:  S K Kaan; C H Cho
Journal:  Inflamm Res       Date:  1996-08       Impact factor: 4.575

5.  Hemodynamic effect of propranolol on portal hypertension in patients with HBsAg-positive cirrhosis.

Authors:  C W Kong; C S Lay; Y T Tsai; S D Lee; K H Lai; K J Lo; B N Chiang
Journal:  Dig Dis Sci       Date:  1986-12       Impact factor: 3.199

6.  Reductions in portal pressure by selective beta 2-adrenoceptor blockade in patients with cirrhosis and portal hypertension.

Authors:  D Bihari; D Westaby; A Gimson; I Crossley; J Harry; R Williams
Journal:  Br J Clin Pharmacol       Date:  1984-06       Impact factor: 4.335

Review 7.  The medical prevention of variceal bleeding.

Authors:  D Lebrec
Journal:  Intensive Care Med       Date:  1988       Impact factor: 17.440

8.  Changes in blood flow, portal pressure and shunting during the development of cirrhosis in response to beta-blockade.

Authors:  M McLaren; S Braye; J Fleming; S Karran; I Taylor
Journal:  Gut       Date:  1987-06       Impact factor: 23.059

9.  Nonsurgical management of emergency hemorrhage from esophageal varices.

Authors:  E R Schiff
Journal:  World J Surg       Date:  1984-10       Impact factor: 3.352

10.  Prophylaxis of first variceal hemorrhage in patients with liver cirrhosis.

Authors:  T Sauerbruch; G Kleber; A Gerbes; G Paumgartner
Journal:  Klin Wochenschr       Date:  1986-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.